# EDGAR Filing Document

**Accession Number:** 0001892728
**File Stem:** 0001213900-25-064283
**Filing Date:** 2025-7
**Character Count:** 6851
**Document Hash:** 77c4cb7be05988e7866eebae0911c18d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-064283.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001213900-25-064283

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250715

**DATE AS OF CHANGE**: 20250715

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABVC BIOPHARMA, INC.
- **CENTRAL INDEX KEY:** 0001173313
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 260014658
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-84759
- **FILM NUMBER:** 251125129

**BUSINESS ADDRESS:**
- **STREET 1:** 44370 OLD WARM SPRINGS BLVD.
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-668-0881

**MAIL ADDRESS:**
- **STREET 1:** 44370 OLD WARM SPRINGS BLVD.
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** American BriVision (Holding) Corp
- **DATE OF NAME CHANGE:** 20160111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METU BRANDS, INC.
- **DATE OF NAME CHANGE:** 20150908

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECOLOGY COATINGS, INC.
- **DATE OF NAME CHANGE:** 20080821
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jiang Eugene
- **CENTRAL INDEX KEY:** 0001892728

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 1197 LA PLURISSIMA PL
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94539

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**ABVC BIOPHARMA, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**00091F304**

*(CUSIP Number)*

**Eugene Jiang**<br>Chairman & Chief Business Officer<br>44370 Old Warm Springs Blvd.<br>Fremont CA 94538<br>(510) 668-0881

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00091F304** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Eugene Jiang** | Name of reporting person<br>**Eugene Jiang** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**3102265.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**3102265.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**131159.00** | Aggregate amount beneficially owned by each reporting person<br>**131159.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**18.50%** | Percent of class represented by amount in Row (11)<br>**18.50%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The Reporting Person holds 131,159 shares directly; his remaining voting power is a result of certain voting agreements that provide him with sole voting power over an aggregate of 2,141,407 shares held by others, as more fully described herein and sole voting power over 829,699 shares held by YuanGene Corporation.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
ABVC BIOPHARMA, INC.

**(c) Address of Issuer's Principal Executive Offices:**
44370 Old Warm Springs Blvd., Fremont, CA, 94538

**Item 4. Purpose of Transaction**

Certain of the Issuer's shareholders sought to grant the Reporting Person voting rights with respect to such shareholder's shares.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person has voting control over 3,102,265shares of Common Stock of the Issuer, which represents 18.50% of the outstanding and issued Common Stock, based on 16,773,261 shares of the Issuer's Common Stock issued and outstanding as of June 27, 2025.

**(b)**
Please refer to rows 7-12 on the cover page.

**(c)**
Between June 20, 2025 and July 1, 2025, the Issuer sold an aggregate of 153,850shares (the "Shares") of its Common Stock to Non-U.S. Persons (as defined in Regulation S under the Securities Act) (the "Investors"), pursuant to Regulation S thereunder ("Regulation S"). The Company received aggregate gross proceeds of $200,000. Each of the Investors entered into a Voting Rights Proxy Agreement, pursuant to which he/she agreed to transfer all of his/her voting rights to the Reporting Person for the maximum time permitted by law.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Other than as described in this Schedule, to the knowledge of the Reporting Person, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Person and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Eugene Jiang

**Signature:** /s/ Eugene Jiang

**Name/Title:** Eugene Jiang, Chairman & Chief Business Officer

**Date:** 07/15/2025